Clinical Trial Update: Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing RT001 for safety and efficacy in treating moderate to severe lateral canthal lines has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lateral Canthal Lines

Drugs mentioned

• RT001

Snippet

Sponsor: Revance Therapeutics, Inc. | Conditions: Lateral Canthal Lines | Phase 2 | Status: COMPLETED